[go: up one dir, main page]

WO2007053165A9 - Biopuce a proteines virales et ses utilisations - Google Patents

Biopuce a proteines virales et ses utilisations

Info

Publication number
WO2007053165A9
WO2007053165A9 PCT/US2006/001018 US2006001018W WO2007053165A9 WO 2007053165 A9 WO2007053165 A9 WO 2007053165A9 US 2006001018 W US2006001018 W US 2006001018W WO 2007053165 A9 WO2007053165 A9 WO 2007053165A9
Authority
WO
WIPO (PCT)
Prior art keywords
coronavirus
sars
virus
protein
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/001018
Other languages
English (en)
Other versions
WO2007053165A3 (fr
WO2007053165A2 (fr
Inventor
Heng Zhu
Mike Snyder
Jian Wang
Guozhen Liu
Shaohui Hu
Ghil Jona
Xiaowei Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of WO2007053165A2 publication Critical patent/WO2007053165A2/fr
Publication of WO2007053165A9 publication Critical patent/WO2007053165A9/fr
Anticipated expiration legal-status Critical
Publication of WO2007053165A3 publication Critical patent/WO2007053165A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Definitions

  • SARS-CoV severe acute respiratory syndrome
  • SARS-CoV encodes two RNA-dependent replicases Ia and Ib, a spike (S) protein, a small envelope (E) protein, a membrane (M) protein, and a nucleocapsid (N) protein, as well as nine predicted proteins that lack significant similarity to any known proteins.
  • the WHO classification for SARS infection in adults is based on four different criteria: fever, respiratory symptoms, close proximity to infected individuals and radiological evidence of lung infiltrates (3).
  • RT-PCR reverse transcription-PCR
  • ELISAs Indirect ImmunoFluorescence Test
  • RT-PCR is sensitive and specific and useful during the period of infection (4-7).
  • samples such as nasopharyngeal or bronchial alveolar aspirates from SARS patients is a dangerous procedure that can put health care workers at high risk.
  • ELISA assays tend not to be highly sensitive and usually require large amounts of sample (8-11).
  • existing ELISA assays such as one manufactured by Euroimmun, use whole viral extracts, thereby increasing the chance of false- positives due to cross-reactivity with proteins from other viruses and resulting in misdiagnosis.
  • a IIFT kit Euroimmun, Germany
  • IIFT limitations include (1) difficulty in diagnosis in the urgent acute phases of the disease, (2) failure to diagnose ⁇ 5% of sera that contain high concentrations of anti-nuclear factor, and 3) visual inspection of fluorescently stained cells which is both subjective and of modest throughput. Thus, more tests for diagnosing the disease need to be developed.
  • virus protein microarrays useful to diagnose (or aid in the diagnosis of), monitor and assess viral infection in an individual in need thereof.
  • Virus protein microarrays of the present invention comprise viral protein(s) that are useful for identifying viral antibodies in a biological sample, such as serum or any antibody- containing fluid or tissue. The presence of viral specific antibodies (antibodies that bind a virus protein present on the array) in a biological sample being assessed indicates that the individual from whom the sample was obtained is or was infected by the vims of which the protein is a component.
  • virus protein microarrays of the present invention are useful to determine or aid in the determination of infection (currently or in the past) of an individual (human or nonhuman) by a virus of interest.
  • virus protein microarrays are useful in diagnosing or aiding in the diagnosis of infection by a wide variety of viruses, as well as in monitoring the course of infection of an individual by a virus of interest. They can be used to determine the presence/absence and/or quantity of antibodies in serum and, thus, the presence/absence and/or extent of infection.
  • Particularly useful components of virus protein microarrays of the present invention are viral protein markers, which are proteins that are characteristic of a virus of interest and recognized by antibodies produced by an individual infected by the virus of interest. Detection of a viral marker protein on a viral protein microarray to which a biological sample (e.g., serum) has been added indicates the presence of antibodies to the virus of interest in the biological sample being assessed.
  • protein includes peptides, polypeptides, protein fragments and proteins
  • viral marker proteins on the protein microarray are specific viral marker proteins. That is, detection of antibodies to such specific viral marker proteins in a biological sample being assessed indicates that the antibodies detected bind only (or essentially only) the viral marker protein(s). hi this embodiment, detection is highly specific.
  • a virus protein microarray of the present invention can comprise any of a wide variety of protein(s), including, but not limited to, all protein(s) from all viruses or one or more marker protein(s) from all viruses (either of which can be seen to be a universal virus protein microarray); all protein(s) from a group of viruses or one or more marker protein(s) from a group of viruses (e.g., all RNA viruses, all Coronavirases, all flu viruses); all protein(s) from a single virus or one or more marker protein(s) from a single virus (e.g. from the SARS Coronavirus).
  • all protein(s) from all viruses or one or more marker protein(s) from all viruses either of which can be seen to be a universal virus protein microarray
  • all protein(s) from a group of viruses or one or more marker protein(s) from a group of viruses e.g., all RNA viruses, all Coronavirases, all flu viruses
  • virus protein microarrays of the present invention optionally additionally comprise protein(s), referred to as reference protein(s), which are not protein(s) of the virus(es) of interest.
  • reference protein(s) can be protein(s) from a virus in the same class or family as the virus whose presence in a sample is being assessed (e.g., protein(s) from a corresponding virus from one or more different host species, such as a murine, bovine, feline or canine protein that corresponds to a virus that infects the individual (who can be human or nonhuman).
  • reference protein(s) can be protein(s) from the virus of interest that are not marker protein(s) but, for example, protein(s) common to the virus of interest and other viruses (sufficiently similar in these viruses) that antibodies in the biological sample recognize the protein(s) from the virus of interest and the additional viruses.
  • the viral protein microarrays of the present invention are coronavirus protein-microarrays that comprise one or more SARS- Coronavirus (SARS-CoV) proteins and, optionally, proteins from one or more additional coronaviruses other than SARS-CoV.
  • SARS-CoV SARS- Coronavirus
  • these SARS- CoV protein microarrays comprise all SARS-CoV proteins (the entire or essentially/substantially all of the SARS proteome) and protein (e.g., partial proteomes) from one or more (e.g., one, two, three, four, five or more) additional coronaviruses.
  • the SARS-CoV protein microarrays comprise less than all of the SARS-CoV proteins (less than the entire SARS proteome).
  • the SARS-CoV component of the microarray can consist of, for example, proteins and/or protein fragments that, together, do not make up all of the SARS-CoV proteins.
  • the SARS-CoV component of the protein microarray can be one or more marker or signature protein, such as envelope (E) protein or fragments thereof; nucleocapsid (N) protein or fragments thereof; spike protein or fragments thereof; or any other protein encoded by the SARS CoV.
  • the SARS-CoV component can be SARS N protein(s) and/or fragments thereof and C-terminal fragments of the N protein.
  • SARS-CoV protein microarrays of the present invention are useful for identifying antibodies to SARS-CoV in a biological sample, such as serum or any antibody-containing fluid or tissue.
  • a biological sample such as serum or any antibody-containing fluid or tissue.
  • SARS-CoV specific antibodies antibodies that bind a SARS-CoV protein present on the array
  • virus protein niicroarrays of the present invention are useful to determine or aid in the determination of infection (currently or in the past) of an individual (e.g., a human) by SARS-CoV.
  • SARS-CoV protein microarrays of the present invention are useful to monitor and assess SARS-CoV and, as described herein, have been shown to serve as the basis for rapid, sensitive and simple analysis of biological samples for the occurrence of viral specific (e.g., SARS-CoV specific) antibodies.
  • a particular advantage of the protein microarray of the present invention is that it can serve as a rapid, sensitive and simple tool for large-scale identification of viral specific antibodies in sera.
  • the SARS-CoV protein microarray has been used to identify individuals with sera reactive against other coronavirus proteins.
  • Applicants developed a computer algorithm that uses multiple classifiers to predict samples from SARS patients, and used it to predict 206 sera from Chinese fever patients.
  • the test assigned the patients into two distinct groups: those with antibodies to SARS-CoV and those without.
  • Results from use of the SARS-CoV protein microarray correlated well with an indirect immunofluorescence test, and demonstrated that viral infection can be monitored for many months after infection.
  • coronavirus proteome microarrays comprise the entire proteome of the human SARS-CoV virus, the entire proteome of the HCoV-229E virus, and the partial proteomes of human HCoV-OC43, Mouse MHV- A59, Bovine coronavirus BCoV, and Feline coronavirus FIPV.
  • the coronavirus protein microarrays were used to screen serum samples collected from fever and respiratory patients during the period of SARS outbreak in Beijing, China and Toronto, Canada.
  • SARS-CoV protein microarrays an comprise less than the entire proteome of the SARS-CoV virus, less than the entire proteome of the HCoV-229E virus and the partial proteomes of human HCoV-OC43, Mouse MHV- A59, Bovine coronavirus BCoV, and Feline coronavirus FlPV.
  • the present invention also relates to a method of diagnosing or aiding in the diagnosis of a viral infection in an individual through the use of a viral protein microarray of the present invention.
  • a biological sample such as serum
  • a viral infection which can be any type of viral infection including, but not limited to, flu, SARS, infection by West Nile virus, bird flu, and, further, other types of conditions and diseases, such as cancer.
  • the biological sample is contacted with an appropriate viral protein microarray, such as a SARS-CoV protein microarray, under conditions appropriate for binding of antibodies to viral proteins on the microarray.
  • Figure 1 Regions of six coronaviruses represented on the microarray. The positions of the cloned and expressed fragments are marked with light grey bars in the figure. The pink bars represent the SARS features selected as classifiers in the supervised cluster analysis (both A-NN and LR). The light blue bars are the features bound by the MHV infected mouse serum.
  • FIGs 2A-2B Analysis of patient serum samples in a protein microarray format.
  • 2A A SARS-CoV positive serum from a diagnosed SARS-Co V-infected patient in Beijing was tested at eight dilutions. The signals for the five SARS N protein fragments are shown on the chart. The vertical line indicates the detection limit.
  • Figure 2B Examples of coronavirus protein microarrays probed with various sera from SARS- Co V-infected or uninfected individuals. Top left panel: Probing with and anti-GST antibody. Top right panel: Probing with a serum from a SARS patient. The N protein and its fragments were the most antigenic protein on the array (indicated by the yellow boxes in the middle panel).
  • the different coronaviruses are color- coded on the left part of the diagrams.
  • the yellow color is low or background signal on the arrays, whereas the orange color represents signals above the background level.
  • the black box highlights the features that help to classify SARS infected sera from the microarray assays. All the classifiers in the black rectangle are SARS N proteins and SARS N fragments.
  • Figures 4A-4B Models generated by K nearest neighbors (4A) and logistic regression (4B).
  • the cutoff for the prediction is the probability of 0.5, which is indicated by the black horizontal line: a) signals for the selected classifiers, b) confidence calculated from the classifier signals (range from 0 to 1), and c) the IIFT annotations, where the black and white boxes represent IIFT positive and negative, respectively.
  • the black and white boxes represent IIFT positive and negative, respectively.
  • the names of the features that were selected by the Ic-NN and LR models are depicted the names of the features that were selected by the Ic-NN and LR models.
  • Figure 5 Time course analysis of sera reactivity of five Canadian individuals. On the top are graphs from two individuals with non-SARS respiratory disease, whereas on bottom depicts results from 3 SARS-patients. The relative levels of antibodies against 4 of the S ARS N protein-constructs along with that of HCoV-229E N protein were monitored at different times. The vertical lines indicate the time at which the persons were diagnosed as SARS-positive by biochemical assays.
  • Figure 6. List of proteins on a representative microarray or protein chip.
  • Figure 7 shows regions of coronaviruses present on a representative microarray.
  • coronavirus protein microarray to screen human sera for antibodies against human SARS and related coronaviruses.
  • this system has enormous potential to be used as an epidemiological tool to screen human and other sera for many types of viral infections as well as other types of disease (e.g. cancer).
  • a virus protein microarray comprising one or more proteins of a SARS-coronavirus.
  • the one or more proteins of a SARS- coronavirus is selected from the group consisting of: SARS spike (S) protein or a fragment thereof; SARS small envelope (E) protein or a fragment thereof; SARS membrane (M) protein or a fragment thereof; SARS nucleocapsid (N) protein or a fragment thereof; and a SARS protein identified in Figure 6 or a fragment thereof.
  • the one or more proteins of a SARS coronavirus is the N protein or a fragment thereof; for example, the N protein comprises a short lysine-rich region or is a C-terminal fragment of the SARS N protein.
  • the virus protein microarray additionally comprises at least one reference protein.
  • the at least one reference protein can be, for example, from a virus selected from the group consisting of: Human Coronavirus (HCoV) 229E; mouse MHV A59; Bovine coronavirus (BCoV); HCoV OC43; Avian infectious bronchitis virus; Canine coronavirus; Murine hepatitis virus; Porcine epidemic diarrhea virus; Porcine hemagglutinating encephalomyelitis virus; Porcine transmissible gastroenteritis virus; Rat coronavirus; Turkey coronavirus; Rabbit coronavirus; Feline infectious peritonitis virus (FIPV); an animal Torovirus; Berne virus; and Breda virus.
  • a virus protein microarray of the present invention comprises the entire or essentially all of the proteome of a coronavirus, such as SARS coronavirus.
  • the virus protein microarray of this invention can additionally comprise the partial proteome of at least one coronavirus other than SARS coronavirus.
  • the at least one coronavirus other than SARS coronavirus can be, for example, selected from the group consisting of: Human Coronavirus (HCoV) 229E; mouse MHV A59; Bovine coronavirus (BCoV); HCoV OC43; Avian infectious bronchitis virus; Canine coronavirus; Murine hepatitis virus; Porcine epidemic diarrhea virus; Porcine hemagglutinating encephalomyelitis virus; Porcine transmissible gastroenteritis virus; Rat coronavirus; Turkey coronavirus; Rabbit coronavirus; Feline infectious peritonitis virus (FIPV); an animal Torovirus; Berne virus; and Breda virus.
  • HCV Human Coronavirus
  • BCoV Bovine coronavirus
  • HCoV OC43 HCoV OC43
  • a virus protein microarray of the present invention comprises all essentially all of the SARS coronvavirus proteins and at least one protein from a coronavirus which is not SARS coronavirus.
  • This virus protein microarray can additionally comprise at least one of the following protein from a coronavirus which is not SARS coronavirus: all or a portion of the proteome of the HCoV-229E virus; all or a portion of the proteome of human HCoV-OC43; all or a portion of the proteome of Mouse MHV-A59; all or a portion of the proteome of Bovine coronavirus BCoV; all or a portion of the proteome of Feline coronavirus FIPV, all or a portion of the proteome of Avian infectious bronchitis virus, all or a portion of the proteome of Canine coronavirus, all or a portion of the proteome of Murine hepatitis virus, all or a portion of the proteome of Porcine epidemic diarrhea virus, all or
  • a coronavirus protein microarray is also an embodiment of the present invention. It comprises, for example, at least one SARS coronavirus marker protein. It can further comprise, for example, a set of proteins selected from the proteins listed in Figure 6, or fragments thereof, wherein the set of proteins or fragments thereof on the microarray is specific for antibodies to SARS coronavirus proteins and is useful to distinguish between sera that contain antibodies to SARS coronavirus proteins and sera that do not contain antibodies to SARS coronavirus proteins.
  • the coronavirus protein microarray can additionally comprise at least one protein from a coronavirus which is not SARS coronavirus.
  • It can additionally comprise at least one of the following proteins from a coronavirus which is not SARS coronavirus: all or a portion of the HCoV-229E virus; all or a portion of human HCoV-OC43; all or a portion of Mouse MHV-A59; all or a portion of Bovine coronavirus BCoV; all or a portion of Feline coronavirus FIPV, all or a portion of Avian infectious bronchitis virus, all or a portion of Canine coronavirus, all or a portion of Murine hepatitis virus, all or a portion of Porcine epidemic diarrhea virus, all or a portion of Porcine hemagglutinating encephalomyelitis virus, all or a portion of Porcine transmissible gastroenteritis virus, all or a portion of Rat coronavirus, all or a portion of Turkey coronavirus, all or a portion of Rabbit coronavirus, all or a portion of an animal Torovirus, all or
  • a coronavirus protein microarray that comprises at least one SARS coronavirus marker protein can additionally comprise a set of proteins selected from the proteins listed in Figure 6, or fragments thereof, wherein the set of proteins or fragments thereof on the microarray is specific for antibodies to SARS coronavirus proteins and is useful to distinguish between sera that contain antibodies to SARS coronavirus proteins and sera that do not contain antibodies to SARS coronavirus protein
  • a coronavirus protein microarray that comprises at least one SARS cornoavirus marker protein can additionally comprise all or a portion of the HCoV-229E virus; all or a portion of human HCoV-OC43; all or a portion of Mouse MHV- A59; all or a portion of Bovine coronavirus BCoV; all or a portion of Feline coronavirus FIPV, all or a portion of Avian infectious bronchitis virus, all or a portion of Canine coronavirus, all or a portion of Murine hepatitis virus, all or
  • the drag to be assessed can be any type of molecule or compound, such as a small molecule or an antibody.
  • a library of drugs can be contacted with the SARS coronaviras protein microarray or individual drugs can be assessed.
  • the library of drugs can be a library of small molecules.
  • a further embodiment of the invention is a method of assessing the effect of treatment provided to an individual infected with SARS coronavirus, comprising assessing a sample (e.g., a sample of serum) from the individual for antibodies to SARS coronaviras prior to treatment and following treatment and determining if there is a difference in the quantity of antibodies in the individual's serum after treatment, wherein a difference is indicative of an effect of the treatment. For example, a decrease in antibody levels after treatment is an indication that treatment is having an effect.
  • the protein microarray assay offered several advantages relative to the commercially available Euroimmun ELISA assay.
  • the assays were sensitive and functioned at high dilutions allowing small amounts of sera to be used (1/200 dilution was used here instead of the 1/50 commonly used in ELISA assays). This is particularly important for SARS research; the sera are extremely precious and not replaceable. Consistent with an increased sensitivity, more Chinese patients were diagnosed as SARS positive using the protein microarray over the Chinese ELISA assay.
  • the accuracy of the assay described herein is as good as, if not better than, the Euroimmun ELISA assay; 92% vs.
  • Applicants' assay has greater reliability in that multiple antigens are followed and a weighted scoring scheme based on probabilities was developed, instead of relying on the results of one or a mix of antigens. To Applicants' knowledge, this is the first time a probabilistic test of this type has been devised for viral detection using sera and it is expected to be of general utility. Fourth, Applicants' assay can monitor the presence of antibodies to multiple viruses, thus allowing their potential simultaneous detection. Fifth, the present assay can be automated to robotically probe hundreds of sera in parallel, a major advantage over the visual analysis in IIFT. Finally, unlike IIFT, in which results can be masked by the presence
  • Any coronavirus protein microarray of the present invention can comprise at least one SArS coronavirus marker protein that is the SARS N protein or a fragment thereof.
  • the N protein comprises a short lysine-rich region or is, for example, a C-terminal fragment of the SARS N protein.
  • a further embodiment of the present invention is a method for detecting one or more antibodies to a SARS-coronavirus in a sample, which can be any tissue, fluid or organ in which such antibodies occur.
  • the method can comprise, for example, a. providing one or more marker proteins of a SARS-coronavirus; b. combining the one or more marker proteins with the sample; c. determining if interaction occurs between one or more marker proteins and one or more proteins (antibodies) in the sample, wherein the detection of interaction between one or more marker proteins with one or more proteins (antibodies)in the sample is indicative of the presence of one or more antibodies to SARS-coronavirus.
  • the one or more marker proteins are present on a protein microarray.
  • the sample can be a serum sample from an individual or any other sample in which antibodies to SARS coronavirus occur (e.g., but not limited to, sputum, urine, CS fluid, organs such as spleen, kidney, liver, bone marrow, nasal fluids, sweat)
  • This method is useful, for example, wherein the individual is thought to be infected with a SARS-coronavirus or has recovered from infection by a SARS coronavirus.
  • the method is also useful where the individual is suspected of ongoing infection by a SARS-coronavirus and the method is carried out periodically in order to monitor the progression of infection by the SARS coronavirus and/or the effect of treatment.
  • the present invention is a method of identifying a drug that binds to a SARS coronavirus protein, comprising contacting a drug to be assessed for its ability to bind a SARS coronavirus protein with a SARS coronavirus protein microarray (e.g., a microarray of any of the claims herein), under conditions appropriate for binding of the drug to a SARS coronavirus protein and determining if binding occurs, wherein, if binding is detected, the drug to be assessed is a drug that
  • the protein microarray assay monitors exposure to several types of coronaviruses.
  • Applicants have constructed coronavirus protein microarrays that cover proteins from six coronavirus proteomes and have used them to classify sera from potential SARS infected patients.
  • the approaches developed here are applicable to potentially all viruses and are expected to have great impact in epidemiological studies, and possibly in clinical diagnosis.
  • the invention provides protein microarrays or protein chips. Methods of making and using protein chips are described U.S. Patent
  • a microarray of the invention comprises one or more proteins, such as marker proteins, from one or more pathogens.
  • pathogens include viruses, bacteria, and fungi.
  • disease causing viruses that may be used in accord with the methods described herein include: Retroviridae (e.g., human immunodeficiency viruses, such as HTV-I (also referred to as HTLV-III, LAV or HTLV-III/LAV, See Ratner, L. et al., Nature, Vol. 313, Pp. 227-284 (1985); Wain Hobson, S. et al, Cell, Vol. 40: Pp. 9-17 (1985)); HIV-2 (See Guyader et al., Nature,
  • HIV-LP International Publication No. WO 94/00562 entitled "A Novel Human Immunodeficiency Virus”
  • Picornaviridae e.g., polio viruses, hepatitis A virus, (Gust, I. D., et al., Intervirology, Vol. 20, Pp.
  • entero viruses human coxsackie viruses, rhinoviruses, echoviruses
  • Calciviridae e.g., strains that cause gastroenteritis
  • Togaviridae e.g., equine encephalitis viruses, rubella viruses
  • Flaviridae e.g., dengue viruses, encephalitis viruses, yellow fever viruses
  • Coronaviridae e.g., coronaviruses
  • Rhabdoviridae e.g., vesicular stomatitis viruses, rabies viruses
  • Filoviridae e.g., ebola viruses
  • Paramyxoviridae e.g., parainfluenza viruses, mumps virus, measles virus, respiratory syncytial virus
  • Orthomyxoviridae e.g., influenza viruses
  • Bungaviridae e.g., Hantaan viruses, bunga viruses, phleboviruses and Nairo viruses
  • Arena viridae hemorrhagic fever viruses
  • Reoviridae e.g., reoviruses, orbiviurses and rotaviruses
  • Birnaviridae Hepadnaviridae (Hepatitis B virus); Parvoviridae (parvoviruses); Papovaviridae (papilloma viruses, polyoma viruses); Adenoviridae (most adenoviruses); Herpesviridae (herpes simplex virus (HSV) 1 and 2, varicella zoster virus, cytomegalovirus (CMV),
  • coronaviruses are enveloped positive single-stranded RNA viruses with genomes approximately 30 kb in length - the largest of any of the RNA viruses — that replicate in the cytoplasm of host cells without going through DNA intermediates. Coronaviruses have been reported to cause common colds in humans, and to cause respiratory, enteric, and neurological diseases, as well as hepatitis, in animals. Human coronaviruses are usually difficult to culture in vitro, whereas most animal coronaviruses and SARS-CoV can easily be cultured in Vero E6 cells. There are three groups of coronaviruses: Groups 1 and 2 encompass mammalian viruses, whereas Group 3 encompasses avian viruses.
  • coronaviruses are classified into distinct species according to host range, antigenic relationships, and genomic organization.
  • Human coronaviruses were previously reported to belong in Group 1 (HCoV-229E) and Group 2 (HCoV-OC43), and are responsible for mild respiratory illnesses.
  • infectious bacteria include: Helicobacter pylori, Borrelia burgdorferi, Legionella pneumophilia, Mycobacterium sps. (e.g. M. tuberculosis, M. avium, M. intracellulare, M. kansaii, M.
  • Streptococcus pyogenes Group A Streptococcus
  • Streptococcus agalactiae Group B Streptococcus
  • Streptococcus viridans group
  • Streptococcus faecalis Streptococcus bovis
  • Streptococcus (anaerobic sps.), Streptococcus pneumoniae, pathogenic Campylobacter sp., Enterococcus sp., Haemophilus influenzae, Bacillus anthracis, Corynebacterium diphtheriae, Corynebacterium sp., Erysipelothrix rhusiopathiae, Clostridium perfringers, Clostridium tetani, Enterobacter aerogenes, Klebsiella pneumoniae, Pasturella multocida, Bacteroides sp., Fusobacterium nucleatum, Streptobacillus moniliformis, Treponema pallidium, Treponema permur, Leptospira, and Actinomyces israelii.
  • infectious fungi examples include: Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis, Candida albicans.
  • Other infectious organisms i.e., protists
  • Plasmodium falciparum and Toxoplasma gondii examples include: Plasmodium falciparum and Toxoplasma gondii.
  • Genomic information (including nucleotide sequences, amino acid sequences, protein expression information, and/or protein structure information) for a variety of microorganisms may be found in the databases maintained by The Institute for Genomic Research (TIGR) (www.tigr.org) and/or the National Center for Biotechnology Information (NCBI) (www.ncbi.nlm.nih.gov).
  • TIGR The Institute for Genomic Research
  • NCBI National Center for Biotechnology Information
  • bacteria for which genomic information is available include, for example, Agrobacterium tumefaciens str. C58 (Cereon) (NC_003062 & NC_003063), Agrobacterium tumefaciens str. C58 (U.
  • NC_003304 & NC_003305) Aquifex aeolicus (NC_000918), Bacillus halodurans (NC_002570), Bacillus subtilis (NC_000964), Borrelia burgdorferi (NC_001318), Brucella melitensis (NC_003317 & NC_003318), Buchnera sp.
  • NC_002528 Campylobacter jejuni (NC_002163), Caulobacter crescentus -CB 15 (NC_002696), Chlamydia muridarum (NC_002620), Chlamydia trachomatis (NCJ)OOl 17), Chlamydophila pneumoniae AR39 (NC_002179), Chlamydophila pneumoniae CWL029 (NC_000922), Chlamydophila pneumoniae J138 (NC_002491), Clostridium acetobutylicum (NC_003030), Clostridium perfringens (NCJ)03366), Corynebacterium glutamicum (NC_003450), Deinococcus radiodurans (NCJ)01263 & NCJ)01264), Escherichia coli Kl 2 (NC_000913), Escherichia coli O157:H7 (NC_002695), Escherichia coli O157:H7 E
  • nucleatum ATCC 25586 NC_003454
  • Haemophilus influenzae Rd NC_000907
  • Helicobacter pylori 26695 NC_000915
  • Helicobacter pylori J99 NC_000921
  • NC_002662 lactis (NC_002662), Listeria innocua (NC_003212), Listeria monocytogenes EGD-e (NC_003210), Mesorhizobium loti (NC_002678), Mycobacterium leprae (NC_002677), Mycobacterium tuberculosis CDCl 551 (NC_002755), Mycobacterium tuberculosis H37Rv (NC_000962), Mycoplasma genitalium (NC_000908), Mycoplasma pneumoniae (NC_000912), Mycoplasma pulmonis (NC_002771), Neisseria meningitidis MC58 (NC_003112), Neisseria meningitidis (NC_003116), Nostoc sp. (NC_003272), Pasteurella multocida (NC_002663), Pseudomonas aeruginosa (NC_002516), Ralstonia solan
  • NC_003295 & NC_003296 Rickettsia conorii
  • NC_003103 Rickettsia prowazekii
  • Salmonella enterica subsp. enterica serovar Typhi NC_003198
  • Salmonella typhi NC_002305
  • Salmonella typhimurium LT2 NC_003197
  • Sinorhizobium meliloti NC_003047)
  • Staphylococcus aureus subsp. aureus MW2 NC_003923
  • Staphylococcus aureus subsp. aureus Mu50 NC_002758)
  • PCC 6803 (NC_000911), Thermoanaerobacter tengcongensis (NC_003869), Thermotoga maritima (NC_000853), Treponema pallidum (NC_000919), Ureaplasma urealyticum (NC_002162), Vibrio cholerae (NC_002505 & NC_002506), Xanthomonas axonopodis pv. cirri str. 306 (NC_003919), Xanthomonas campestris pv. campestris str. ATCC 33913 (NC_003902), Xylella fastidiosa 9a5c (NC_002488), and Yersinia pestis (NC_003143).
  • archaea for which genomic information is available from TIGR and/or NCBI, include, for example, Aeropyrum pernix (NC_000854), Archaeoglobus fulgidus (NC_000917), Halobacterium sp. NRC-I (NC_002607), Methanococcus jannaschii (NC_000909), Methanopyrus kandleri AV19 (NC_003551), Methanosarcina acetivorans str.
  • NC_000854 Aeropyrum pernix
  • NC_000917 Archaeoglobus fulgidus
  • Halobacterium sp. NRC-I NC_002607)
  • Methanococcus jannaschii NC_000909
  • Methanopyrus kandleri AV19 NC_003551
  • Methanosarcina acetivorans str examples include, for example, Aeropyrum pernix (NC_000854), Archaeoglobus fulgidus
  • NC_003552 Methanosarcina mazei Goel (NC_003901), Methanothermobacter thermautotrophicus (NC_000916), Pyrobaculum aeropliilum (NC_003364), Pyrococcus abyssi (NC_000868), Pyrococcus furiosus DSM 3638 (NC_003413), Pyrococcus horikoshii (NC_000961), Sulfolobus solfataricus (NC_002754), Sulfolobus tokodaii (NC_003106), Thermoplasma acidophilum (NC_002578), and Thermoplasma volcanium (NC_002689).
  • Examples of eukaryotes for which genomic information is available from TIGR and/or NCBI include, for example, Anopheles gambiae, Arabidopsis thaliana, Caenorhabditis elegans, Drosophila melanogaster, Encephalitozoon cuniculi, Guillardia theta nucleomorpli, Saccharomyces cerevisiae, and Schizosaccharomyces pombe.
  • Genomic information for over 900 viral species is available from TIGR and/or NCBI, including, for example, information about deltaviruses, retroid viruses, satellites, dsDNA viruses, dsRNA viruses, ssDNA viruses, ssRNA negative-strand viruses, ssRNA positive-strand viruses, unclassified bacteriophages, and other unclassified viruses.
  • GenBank# examples of nucleotide and protein sequences of coronaviruses and coronavirus proteins are available in GenBank as follows: Virus Gene GenBank#
  • Example 1 Development of a coronavirus protein microarray and a SARS detection assay A protein microarray approach was developed to rapidly identify SARS-CoV and other coronavirus-infected patients with high sensitivity and accuracy. Gene or gene fragments that cover the entire genome of SARS-CoV, and the majority of the HCoV-229E and MHV A59 genomes were amplified using PCR and cloned into a yeast expression vector that expresses the viral proteins with glutathione-S-transferase (GST) at their N-terminus (Fig. 1). Using the limited sequence information available at the time, regions of the BCoV, HCoV-OC43 and FIPV genomes were also cloned (Fig. 1).
  • GST glutathione-S-transferase
  • Applicants fabricated a microarray containing the 82 purified proteins.
  • Serial dilutions prepared from four serum samples collected from Chinese patients who were clinically diagnosed as SARS-positive and who also tested positive by a local ELISA assay (one very strong positive, one medium, and 2 weak) were used to probe the array.
  • the presence of human anti-SARS antibodies was detected with Cy-3 labeled goat anti-human IgG antibodies (12-16).
  • the sensitivity of the microarray assay is extremely high; reactivity is readily detected at 1 : 10,000 fold dilution for the strong positive serum and 1 :800 for the weakly positive sera.
  • the assay is approximately 50-fold more sensitive than ELISA assays performed using the same sera.
  • less than l ⁇ l of serum is needed for the protein microarray assay, which is crucial since the sera from SARS patients are extremely precious.
  • the coronavirus protein microarrays were used to screen sera from 399 Canadian and 203 Chinese infected and non-infected individuals in a double blind format.
  • the Canadian samples included 181 clinical and laboratory-confirmed SARS- CoV sera (see methods) (3), as well as anonymized clinical samples from patients who had presented with respiratory illness during the outbreak period, but who failed to meet the case definition, and did not develop SARS.
  • Other S ARS-Co V-negative sera were from asymptomatic healthcare workers.
  • the Chinese sera were from patients with fever during the SARS outbreak; some of these were classified as SARS-positive and others as SARS -negative.
  • each of the 82 purified coronavirus proteins was spotted in duplicate on eight identical blocks per microscope slide. Human IgG protein was also included as positive control (see below).
  • the amount of immobilized coronavirus proteins and protein fragments present on the microarray was quantified by probing with anti-GST antibodies (Fig. 2B). Reactive protein was evident for each protein.
  • the serum samples were screened at a 200-fold dilution, and the bound antibodies were detected with Cy-3 labeled goat anti-human IgG. The signals were analyzed using algorithms Applicants developed. Positive sera usually exhibited strong reactivity for approximately 10% of the proteins on the microarrays.
  • SARS-N-C2 The full-length and two C-terminal derivatives of SARS N-protein were strongly recognized by the antibodies present in the SARS-CoV infected patient sera, but not in sera from non- infected individuals (Fig. 2B).
  • the SARS-CoV infected sera from the Chinese and Canadian patients showed little cross-reactivity with proteins of other coronaviruses. including N proteins, on the array.
  • One exception is that many (88%) of the sera from the Chinese patients showed a slight reactivity to the first half of BCoV N-protein, which shares -40% identity through its first 210 amino acids with the SARS-CoV N protein.
  • the sera from infected Canadian patients did not react with this protein, hi addition, approximately 20% of the sera from both SARS positive and negative Canadian individuals specifically recognized the HCoV-229E N protein, but not the N proteins from the other species. We expect that many Canadian patients may have been exposed to HCoV-229E (see below).
  • a mouse-infected serum recognized the MHV A59 N protein, whereas control mouse sera did not react with proteins on the array.
  • This serum also cross-reacted with the N protein from BCoV, and not with proteins from other coronaviruses. Since the N proteins from MHV and BCoV share 70.7% identity and 87.9% similarity over their entire protein sequences, cross reactivity between these two proteins is not surprising.
  • Applicants analyzed the results obtained from the Canadian patients using computational approaches.
  • the sera were first clustered according to the relative signal intensities of all the coronavirus proteins immobilized on the microarrays in an unsupervised fashion(17).
  • the sera fell into two major groups, which upon subsequent comparison with clinical IIFT data were largely correlated with SARS-positive and SARS-negative sera (Fig. 3).
  • the unsupervised method correctly predicted 138 of 181 infected serum samples (76% sensitivity, with sensitivity defined as the percentage of correct positives of the total positives), and 210 of 218 sera from healthy individuals (96% specificity, with specificity defined as the percentage of correctly classified negatives out of the total negatives).
  • k ⁇ NN measures the similarity between a new case and all the known cases to make a prediction, and is determined by the identities of its 'k' closest neighbors (Fig. 4A).
  • Fig. 4A five features were selected by the algorithm as the best classifiers: SARS N (pEGH-55 (Y)), SARS N (pEGH-B4), SARS N-Cl (pEGH-B7), 229E-S 1/4, and SARS S (1st half (Y)) (note that 229E-S1/4 negatively correlates with SARS).
  • LR Regression
  • LR is a generalized linear regression for binary responses (Fig. 4B).
  • the features selected by LR included SARS N-Cl (pEGH-B7), SARS N (pEGH-55) (Y) 5 SARS N (pEGH-B4), and SARS N-C2 (pEGH-B8 #1).
  • the accuracy of this model was 92% (89% sensitivity and 94% specificity).
  • k-NN or LR performed better, Applicants took advantage of the receiver operating characteristic curve (ROC)(21) (data not shown), and plotted the rate of true positives against that of false positives at different cutoff points.
  • the quality of the model was measured using the area under the curve (AUR).
  • the microarray approach was also compared with a local ELISA used in China that used only the purified N protein.
  • a set of 147 serum samples collected from fever patients during the SARS outbreak in China was used to probe the coronavirus protein microarray. The SARS status of these patients is not known. Similar to the results presented above, Applicants found 85% agreement between the predictions made from the microarray assay and those made from the ELISA; all 70 sera that were SARS-CoV positive by the ELISA were also positive by microarray. The microarray identified an additional 21 sera as SARS-CoV positive that were not found using the ELISA.
  • a serum test relative to a nucleic acid diagnostic test is that anti-SARS antibodies can potentially be detected long after infection. Applicants therefore tested how long anti-SARS antibodies remained present in recovering patients post infection. Serum samples that had been drawn from five Canadian individuals (two respiratory illness other than SARS and three confirmed SARS-CoV cases) at different times post-infection were tested using the protein microarrays (Fig. 5). Reactivity to 5 N proteins (4 SARS N proteins, and one CoV-229E N protein) was scored. Sera from non-SARS patients (1 and 4 in Fig. 5) did not exhibit significant reactivity to any of the five SARS-CoV markers.
  • Example 7 Extending the protein microarray approach to detecting other coronaviruses
  • HCoV-229E proteins from other human coronaviruses, such as the HCoV-229E, were included on the microarray, thus, allowing the detection of antibodies directed towards other coronaviruses (25-27).
  • HCoV-229E related proteins as classifiers, Applicants identified 82 serum samples with substantial signal (52 of 218 S ARS-Co V- negative (23.9%) and 30 of the 218 SARS-Co V-positive sera (13.8%).
  • the presence of 52 HCoV-229E positive sera in SARS-CoV-negative patients suggests that these patients were or had been infected with the HCoV-229E.
  • Serum samples The 399 serum samples tested from Canada included 40 acute and 164 convalescent sera from 92 patients who met the clinical and laboratory criteria for SARS-CoV infection during the Toronto SARS outbreak in 2003. Sera from 112 Toronto patients who presented with non-SARS respiratory illness, and 83 sera from health professionals were also included. None of the acute, all 164 of the convalescent and 17 of the sera from 12 healthcare workers demonstrated IgG antibodies as detected using the Euroimmun IIFT test. All positive results were repeated and any unexpected result was confirmed using the SARS-CoV neutralization assay. The Chinese samples were collected from several hospitals in Beijing by the BGI. These sera were collected from 147 non-confirmed fever patients and 56 respiratory patients (36 confirmed SARS-patients and 20 none-SARS individuals). Gene cloning from the coronaviruses
  • SARS-CoV Generas of viruses
  • the SARS ORFs were amplified by RT- PCR from the SARS-CoV isolate BJOl and cloned into pGEM-T.
  • the SARS ORFs were further cloned into a yeast GST expression vector (pEGH) described previously (12). The same approach was used for the cloning of other coronavirus genes. All clones were confirmed by sequencing their inserts.
  • Protein purification and protein microarray fabrication The constructs were transformed into yeast and proteins were purified as described previously (13). The GST fusion proteins were eluted into printing buffer containing 20% glycerol in 50 mM HEPES (pH 7.0). For samples that exhibited low yields, the purification was repeated using 50 ml cultures and/or up to 4 times.
  • the coronavirus protein microarrays were fabricated by spotting the purified proteins along with positive control proteins onto 8-pad FAST slides (Schleicher & Schuell, Germany) using a microarrayer (Bio-Rad, USA). The printed arrays were allowed to sit at 4° C overnight and stored at -20° C.
  • Cy3- and Cy5-labled anti-human IgG and IgM antibodies were incubated on microarrays at 1000-fold dilution. The arrays were washed with PBS buffer, briefly rinsed with water, and dried. The slides were scanned and signals analyzed using the GenePix Pro 3.0 software.
  • X-Nearest Neighbor stores a group of known cases and classifies new instances based on a similarity measure (19).
  • the new instance is classified according to the identities of its nearest neighbors.
  • the number of the neighbors is determined by the parameter k, and the similarity is measured as the Euclidean distance using the signals of the classifiers.
  • the best parameters were selected in the learning process and applied in the predicting process. In the learning process, all parameters including possible k's and candidate classifiers were tested and their performance was evaluated by ten fold cross validation to find the best values (29). In the prediction process, the k nearest neighbors were retrieved for each new instance, and classifications were made according to the memberships of the neighbors.
  • Logistic regression is a generalized linear regression model designed for binary responses(20). However, no missing values for the candidate features are allowed in model construction; thus the number of sera analyzed ( ⁇ 370) was less than the total screened.
  • the candidate features were selected by the model using both-direction stepwise search with Akaike information criterion (30). We performed this analysis using S-Plus 6.1 software that selected the top four features out of the candidate list for the prediction step. Finally, the probability of each serum to be positive was calculated using those features, and those that had a value greater than 0.5 were classified as SARS-CoV positive.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L’invention concerne une biopuce à protéines virales qui constitue un outil rapide, sensible et simple pour l’identification d’anticorps spécifiques à des virus dans du sérum, par exemple une biopuce à protéines du coronavirus du SRAS. L’invention concerne également des procédés de mise en œuvre de la biopuce à protéines.
PCT/US2006/001018 2005-01-11 2006-01-11 Biopuce a proteines virales et ses utilisations Ceased WO2007053165A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64282405P 2005-01-11 2005-01-11
US60/642,824 2005-01-11

Publications (3)

Publication Number Publication Date
WO2007053165A2 WO2007053165A2 (fr) 2007-05-10
WO2007053165A9 true WO2007053165A9 (fr) 2007-07-05
WO2007053165A3 WO2007053165A3 (fr) 2008-01-31

Family

ID=38006339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/001018 Ceased WO2007053165A2 (fr) 2005-01-11 2006-01-11 Biopuce a proteines virales et ses utilisations

Country Status (1)

Country Link
WO (1) WO2007053165A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2023142A1 (fr) * 2007-07-30 2009-02-11 Mikrogen Molekularbiologische Entwicklungs-GmbH Dosage immunologique utilisant des protéines de capsides nucléiques recombinantes pour la détection d'anticorps aux coronavirus humains
EP3058370A4 (fr) * 2013-10-14 2017-08-30 The University of North Carolina at Chapel Hill Méthodes et compositions pour le diagnostic du coronavirus et thérapeutique
CN109734802A (zh) * 2019-03-18 2019-05-10 扬州大学 一种重组猪流行性腹泻病毒n、s蛋白单克隆抗体的制备方法
CN110273024A (zh) * 2019-05-08 2019-09-24 广西大学 基于猪流行性腹泻病毒m基因的荧光定量pcr检测引物及其试剂盒
GB201910730D0 (en) * 2019-07-26 2019-09-11 Randox Teoranta Bovine Pathogen Array
CN111679083B (zh) * 2020-02-17 2025-06-20 浙江大学医学院附属第一医院 用于检测新型冠状病毒抗体的碱性磷酸酶蛋白芯片试剂盒及其制备方法
CN111596064B (zh) * 2020-04-28 2023-03-31 江苏省农业科学院 同时检测pedv和tgev的速测卡及其制备、使用方法
CN112067712B (zh) * 2020-08-18 2022-11-01 上海纳米技术及应用国家工程研究中心有限公司 一种诊断新型冠状病毒的挥发性标志物及其应用
TWI767434B (zh) * 2020-12-01 2022-06-11 國立成功大學 蛋白質微陣列、其檢測方法、其用途及含有該蛋白質微陣列之試劑盒
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2523875A1 (fr) * 2003-04-28 2004-11-11 Public Health Agency Of Canada Sequences de nucleotides et d'acides amines du virus du sras, et utilisations associees
WO2005043111A2 (fr) * 2003-07-14 2005-05-12 Ciphergen Biosystems, Inc. Marqueurs biologiques seriques pour le sras

Also Published As

Publication number Publication date
WO2007053165A3 (fr) 2008-01-31
WO2007053165A2 (fr) 2007-05-10

Similar Documents

Publication Publication Date Title
Zhu et al. Severe acute respiratory syndrome diagnostics using a coronavirus protein microarray
CN112034174B (zh) 一种多肽芯片及其在病毒检测上的应用
Bellini et al. The challenges and strategies for laboratory diagnosis of measles in an international setting
Chan et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63
He et al. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus
Lessa-Aquino et al. Identification of seroreactive proteins of Leptospira interrogans serovar copenhageni using a high-density protein microarray approach
Di et al. Monoclonal antibody-based antigen capture enzyme-linked immunosorbent assay reveals high sensitivity of the nucleocapsid protein in acute-phase sera of severe acute respiratory syndrome patients
Burbelo et al. Emerging technologies for the detection of viral infections
Maine et al. Development and clinical evaluation of a recombinant-antigen-based cytomegalovirus immunoglobulin M automated immunoassay using the Abbott AxSYM analyzer
WO2005016132A2 (fr) Diagnostic pour le virus du sras
TW201300421A (zh) 用於偵測豬繁殖及呼吸道綜合症病毒（ｐｒｒｓｖ）之試劑及方法
WO2007053165A9 (fr) Biopuce a proteines virales et ses utilisations
Yuan et al. Molecular modeling and epitopes mapping of human adenovirus type 3 hexon protein
Lagousi et al. Development of an enzyme-linked immunosorbent assay (ELISA) for accurate and prompt coronavirus disease 2019 (COVID-19) diagnosis using the rational selection of serological biomarkers
Javadi Mamaghani et al. In-silico design of a multi-epitope for developing sero-diagnosis detection of SARS-CoV-2 using spike glycoprotein and nucleocapsid antigens
Martinaud et al. Evaluation of the Quotient® MosaiQ™ COVID-19 antibody microarray for the detection of IgG and IgM antibodies to SARS-CoV-2 virus in humans
Bubonja-Šonje et al. Diagnostic accuracy of three SARS-CoV2 antibody detection assays, neutralizing effect and longevity of serum antibodies
Evans et al. Cross reactivity of neutralizing antibodies to the encephalitic California Serogroup orthobunyaviruses varies by virus and genetic relatedness
Simon et al. Nasopharyngeal carcinoma patients from Norway show elevated Epstein-Barr virus IgA and IgG antibodies prior to diagnosis
JP5033127B2 (ja) 単純ヘルペスウイルス２型を検出するための方法および組成物
Wang et al. Identification and characterization of two linear epitope motifs in hepatitis E virus ORF2 protein
Kumar et al. Comprehensive mapping of SARS-CoV-2 peptide epitopes for development of a highly sensitive serological test for total and neutralizing antibodies
US20090305899A1 (en) Compositions and methods for determining immune status
US20050100883A1 (en) Peptide-based diagnostic reagents for SARS
Davidson et al. Comparative analysis of three laboratory based serological assays for SARS-CoV-2 in an Australian cohort

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: RULE 160.1 EPC

122 Ep: pct application non-entry in european phase

Ref document number: 06844066

Country of ref document: EP

Kind code of ref document: A2